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Cytembena (cytembene; 2-butenoic acid; 3-bro-
mo-4(4-methoxyphenyl)4-oxo-, sodium; NSC 104801;
CAS No. 21739-91-3) was selected for testing by
the Carcinogenesis TestingProgram, National Can-
cer Institute (now part ofthe National Institute of
Environmental Health Sciences/National Toxicol-
ogy Program) because preliminary clinical results
from Czechoslovakia indicated that this chemical
might have use as a cytostatic agent (1-4). Clinical
trialsinthe United States werediscontinued because
no apparent antineoplastic effects were seen (5-7).
Methods
Male and female inbred Fischer344rats and male
and female hybrid B6C3F1 mice, obtained from
Frederick Cancer Research Center, were used in
this study. Control and treated groups comprised
50 animals ofeach species and sex. For 104 consec-
utive weeks all groups were fed Wayne Lab Blox.
Three times per week treated groups were given
intraperitoneal injections of7 or 14 mg/kg (forrats)
and 12 or 24 mg/kg (for mice) ofcytembena (99.4%
pure). Control groups received 0.9% saline injec-
tions.
This carcinogenesis bioassay was conducted dur-
ing January 1977 to January 1979 by Southern
Research Institute under a subcontract to Tracor
Jitco (prime contractor for the testing program).
All animals that died during the study or that
were killed at the end ofthe exposure period were
subjected to a gross necropsy and a complete
histopathological examination. Statistical analyses
comparing survival and numbers of animals with
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specific site tumors were done with trend tests and
pairwise comparisons (8-11). The study design
conformed to the NCI Guidelines for carcinogen
bioassay (12).
Results
Mean body weights of dosed and vehicle-control
rats were comparable throughout the bioassay.
Mean body weights of dosed and vehicle-control
mice were comparable for the first 73 weeks ofthe
bioassay; mean body weight of the high dose male
mice was slightly lower than that of the vehicle
controls after 73 weeks, and that of the high dose
female mice was lower after week 87.
Survivalformalerats was significantlydecreased
(p < 0.001) in the dosed groups relative to controls
(29/50 control, 12/50 low dose, 12/50 high dose),
whereas survival rates for female rats were compa-
rable (30/50, 33/50, 28/50). All male mice groups
exhibited markedly decreased survival compared to
historic rates (20/50, 19/50, 12/50); female mice
survival was comparable among groups (41/50,
33/50, 34/50).
Increased tumor incidences were diagnosed in
male rats for mesotheliomas and in female rats for
mammary gland fibroadenomas (Table 1).
The numbers of cytembena-treated rats with
other specific site tumors and the frequencies of
cytembena-treated mice with lesions did not. differ
significantly fromthose observedincontrols. Tables
2 (rats) and 3 (mice) list those primary tumors
found in at least three animals of any one group.
Discussion
The increased number of treated male rats with
mesotheliomas in the tunica vaginalis and in multi-
ple organs clearly associates these lesions with
cytembena administration (Table 1). MalignantTable 1. Primary tumor increases in male and female F344 rats given cytembena by intraperitoneal injection.
Male Female
Vehicle Vehicle
Tumor control 7 mg/kg 14 mg/kg control 7mg/kg 14 mg/kg
Marnmary gland fibroadenomasa 0/50 2/50 2/50 13/49 22/50 36/50b
Mesothelioma mesentery 0/50 3/50 0/50 0/49 0/50 0/50
Mesothelioma multiple organsc 3/50 26/50b 26/50b 0/49 0/50 2/50
Mesothelioma tunica vaginalisd 0/50 11s50b 10/50e - - _
aSignificant dose-related trend for females (p < 0.001).
bSignificantly greater than controls (p < 0.001).
CSignificant dose-related trend for males (p < 0.001).
dSignificant dose-related trend for males (p < 0.05).
eSignificantly greater than controls (p < 0.005).
Table 2. Primary tumors in male and female F344 rats given cytembena by intraperitoneal injection.
Male Female
Vehicle Vehicle
Tumor control 7 mg/kg 14 mg/kg control 7 mg/kg 14 mg/kg
Adrenal pheochromocytoma 12/50 7/50 7/49 3/49 2/50 1/50
Hepatocellular neoplastic nodule 1/49 1/50 1/50a 0/49 1/50 4/50
Leukemia 20/50 12/50 22/50 8/49 8/50 8/50
Lymphoma 0/50 0/50 0/50 0/49 3/50 1/50
Mesentery lipoma 0/50 2/50 2/50 0/49 0/50 3/50b
Pancreatic islet-cell adenomaorcarcinoma 3/50 5/50 4/49 0/49 1/48 1/49
Pituitary adenoma 8/50 3/50 5/50 14/47 13/46 16/47
Subcutaneous fibroma or fibroadenoma 3/50 0/50 2/50 0/49 0/50 2/50
Testicular interstitial cell 47/50 41/50 47/50 - - -
Thyroid C-cell adenoma or carcinoma 5/50 4/49 4/50 8/49 6/48 8/49
Thyroid follicular-cell adenoma or 3/50 1/49 3/50 1/49 2/48 2/49
carcinoma
Uterine endometrial stromal polyp - - - 16/49 11/50 11/50
aOne other male rat had a hepatocellular carcinoma.
bOne other female rat had a sarcoma, NOS (not otherwise specified).
Table 3. Primary tumors in male and female B6C3F1 mice given cytembena by intraperitoneal injection.
Male Female
Vehicle Vehicle
Tumor control 12 mg/kg 24 mg/kg control 12 mg/kg 24 mg/kg
Circulatory system hemangiosarcoma 1/50 3/50 1/50 0/50 1/50 2/50
Harderian gland adenoma 2/50 3/50 1/50 1/50 0/50 1/50
Hepatocellular adenoma 6/49 5/49 6/50 0/50 0/48 4/49
Hepatocellular carcinoma 10/49 13/49 7/50 3/50 3/48 2/49
Lymphoma 5/50 4/50 3/50a 8/50 8/50a 11/50b
Lung alveolar/bronchiolar adenoma or 6/50 7/47 5/49 7/50 4/49 2/48
carcinoma
Pituitary adenoma 0/47 0/42 0/44 1/47 3/46 0/44
Pituitary carcinoma 0/47 0/42 0/44 1/47 0/46 1/44
Thyroid follicular-cell adenoma 1/44 0/44 2/46 3/49c 2/48 2/49c
Uterine endometrial stromal polyp or - - - 0/49 3/48 2/50
sarcoma
aOne other animal had leukemia.
bTwo other females had leukemia.
cOne other female had a thyroid follicular-cell carcinoma.
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mesotheliomas involved the serosal surfaces of
most ofthe abdominal organs including the spleen,
pancreas, mesentery, urinary bladder, seminal ves-
icles, prostate, testicles (tunica vaginalis and epi-
didymis), peritoneum, abdominal wall, and dia-
phragm. Grossly, abdominaldistentionwasfrequently
observed. This distention resulted from accumula-
tion of large quantities of dark brown peritoneal
fluid. Most serous surfaces manifested a rough,
granular appearance. The mesentery was usually
thickened and nodular.
Histologically, most mesotheliomas were of the
papillary type. There were numerous villous or
papillaryprojectionsontheseroussurfaceofaffected
organs. The stromal element ofthe villi consisted of
connective tissue cells. The villi orprojections were
covered by prominent mesothelial cells. The cell
nuclei had moderately dense stippled chromatin
and were uniformly round to oval. Most nuclei had
one or two small nucleoli. The cytoplasm was
distinct and abundant. Mitotic figures were com-
monly seen. There was frequent invasion of the
abdominal wall and diaphragm. Invasive cells were
usuallycuboidal orpolygonaland sometimes formed
pseudoglandular acini. These cells were usually
more pleomorphic and were arranged in solid nests
or cords.
Cytembena induced an increased incidence of
female rats with proliferative and neoplastic lesions
ofthe mammary gland. A high incidence ofatypical
mammarygland fibroadenomas was observed inthe
female rats. These neoplasms were characterized
bynumerouscysticductswithextensiveperiductular
fibrosis and cystic glandular hyperplasia. Many of
the ducts contained numerous intraductular papil-
lary growths. Epithelial cells covering the papillary
projections often showed piling up ofcell nuclei. In
some areas, there were dilated periductular acini.
The epithelial cells lining these spaces stained
deeply basophilic and frequently showed a loss of
normalcellularorientation orpolarity. Somemitotic
activity was observed in these areas. The variable
degrees of cellular atypia were suggestive ofearly
malignant transformation or change. These lesions
represented a variant ofmammary fibroadenomas.
There was also an increase in the number ofcystic
ducts, cystic hyperplasia, epithelial hyperplasia,
and lobular hyperplasia in the mammary tissue of
dosed female F344 rats.
Positive dose-related trends were observed for
female rats with hepatocellular neoplastic nodules
(p < 0.05) and for female rats with mesentery
lipoma (p < 0.05). Pairwise comparisons between
treatedandcontrolgroupsdidnotyieldanysignificant
differences. These borderline effects were not con-
sidered compound induced. Similarly, a significant
trend (p < 0.05) was calculated forfemale mice with
hepatocellular adenoma; no differences were found
between treated groups and controls or when liver
tumors (adenomas and carcinomas) were consid-
ered together.
In conclusion, under the conditions ofthis bioas-
say, cytembena was carcinogenic for male and
female F344 rats, causing increased numbers of
males with mesotheliomas in the tunica vaginalis
and inmultiple organs and causingincreased frequen-
cies offemales with fibroadenomas in the mammary
glands. Cytembenawasnotcarcinogenic forB6C3F,
mice of either sex (13).
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